Managing warfarin, DOACs, and bleeding risk safely is a high-stakes FNP skill. Drill the INR-monitoring and DOAC-selection scenarios below, each with a full rationale.
Question 1
A 74-year-old female with atrial fibrillation and heart failure with reduced ejection fraction (LVEF 30%) complains of continuous palpitations. Her resting Heart rate is 118 bpm. She currently takes apixaban and lisinopril but no rate-controlling medications. Which medication should the nurse practitioner prescribe?
- A) Initiate oral verapamil therapy immediately.
- B) Initiate oral diltiazem therapy immediately.
- C) Initiate oral amlodipine besylate therapy.
- D) Initiate oral metoprolol succinate therapy.✓
Show rationale
In patients with atrial fibrillation and heart failure with reduced ejection fraction, beta-blockers like metoprolol succinate are the preferred agents for rate control because they provide significant mortality benefits. Non-dihydropyridine calcium channel blockers, such as verapamil and diltiazem, are strictly contraindicated in this population due to their negative inotropic effects, which can significantly worsen heart failure symptoms. Amlodipine is a dihydropyridine calcium channel blocker; while it is safe to use in heart failure, it does not provide atrioventricular nodal blockade and therefore will not control her elevated heart rate.
Question 2
A 55-year-old male presents with knee osteoarthritis and requests medication. He has a history of bleeding gastric ulcer but normal renal function. Which treatment plan is most appropriate?
- A) Initiate oral naproxen and schedule a follow-up visit.
- B) Prescribe oral celecoxib and a proton pump inhibitor.✓
- C) Recommend oral ibuprofen and an over-the-counter antacid.
- D) Start oral meloxicam and a histamine H2 antagonist.
Show rationale
For patients with a history of a bleeding gastric ulcer, the gastrointestinal risk is exceptionally high. Guidelines recommend using a selective COX-2 inhibitor combined with a proton pump inhibitor to minimize recurrent bleeding. Option A is incorrect because naproxen is a nonselective NSAID that significantly increases bleeding risk. Option C is incorrect because ibuprofen combined with a simple antacid does not provide adequate mucosal protection. Option D is incorrect because while meloxicam has some COX-2 selectivity, histamine H2 antagonists are inferior to proton pump inhibitors for preventing NSAID-induced ulcers in high-risk patients.
Question 3
A 71-year-old female with a history of cardioembolic stroke and newly diagnosed nonvalvular atrial fibrillation presents to the clinic. Which medication is the most appropriate choice for secondary stroke prevention?
- A) Initiate aspirin eighty-one milligrams by mouth once daily.
- B) Initiate clopidogrel seventy-five milligrams by mouth once daily.
- C) Initiate apixaban five milligrams by mouth twice daily.✓
- D) Initiate warfarin targeting an international normalized ratio three.
Show rationale
For patients with a cardioembolic stroke secondary to nonvalvular atrial fibrillation, direct oral anticoagulants (DOACs) like apixaban are the preferred first-line agents for secondary prevention. Option C is correct because DOACs offer superior safety profiles and comparable or better efficacy than warfarin. Option D is incorrect because while warfarin is an anticoagulant, it is generally reserved for valvular atrial fibrillation or when DOACs are contraindicated; furthermore, the standard target INR is 2.0 to 3.0, making a strict target of 3.0 inappropriate. Option A and Option B are incorrect because antiplatelet agents like aspirin and clopidogrel are insufficient for preventing cardioembolic stroke and are not recommended for atrial fibrillation management when full anticoagulation is indicated.
Question 4
A patient taking rivaroxaban for deep vein thrombosis is brought to the emergency department with an acute intracranial hemorrhage that requires immediate pharmacological reversal. Which order should the advanced practice registered nurse anticipate?
- A) Administer intravenous andexanet alfa immediately.✓
- B) Administer intravenous idarucizumab therapy immediately.
- C) Administer intravenous protamine sulfate immediately.
- D) Administer intravenous phytonadione therapy immediately.
Show rationale
Andexanet alfa is the specific, FDA-approved reversal agent for direct factor Xa inhibitors like rivaroxaban and apixaban in the setting of life-threatening or uncontrolled bleeding. Idarucizumab is the specific reversal agent for dabigatran, a direct thrombin inhibitor, and would be ineffective here. Protamine sulfate is used to reverse heparin and low-molecular-weight heparins. Phytonadione (vitamin K) is the reversal agent for warfarin and does not reverse the effects of direct oral anticoagulants.
Question 5
A 65-year-old female with Stage 5 CKD not yet on dialysis presents with unexplained epistaxis and gingival bleeding. Her platelet count is 210,000/mcL and PT/INR is normal. What is the underlying pathogenesis of her bleeding presentation?
- A) Accelerated peripheral destruction of circulating platelets
- B) Decreased hepatic synthesis of coagulation factors
- C) Impaired platelet aggregation from retained toxins✓
- D) Increased systemic consumption of fibrinogen stores
Show rationale
Patients with Stage 5 CKD often develop a bleeding diathesis due to uremia. The pathogenesis is not a lack of platelets, but rather impaired platelet aggregation and altered platelet-vessel wall interactions caused by retained toxins like guanidinosuccinic acid. This leads to prolonged bleeding times despite a normal platelet count. Option C accurately describes this uremic platelet dysfunction. Option A is incorrect because the platelet count is normal, ruling out destructive thrombocytopenia. Option B is incorrect because hepatic synthesis of coagulation factors remains intact in isolated CKD, which is supported by her normal PT/INR. Option D describes disseminated intravascular coagulation, which does not align with her isolated mucosal bleeding and stable laboratory profile.
Question 6
A 76-year-old male requires anticoagulation for non-valvular atrial fibrillation. His recent laboratory results reveal a creatinine clearance of 45 mL/min. He prefers a medication he can take once daily with his evening meal. Which prescription is most appropriate?
- A) Initiate rivaroxaban 20 mg taken once daily with food.
- B) Initiate dabigatran 150 mg taken twice daily with food.
- C) Initiate rivaroxaban 15 mg taken once daily with food.✓
- D) Initiate dabigatran 110 mg taken twice daily with food.
Show rationale
For patients with non-valvular atrial fibrillation, rivaroxaban is dosed at 20 mg once daily with the evening meal if renal function is normal. However, in the presence of renal impairment where the creatinine clearance is between 15 and 50 mL/min, the dose must be reduced to rivaroxaban 15 mg once daily. Option A is incorrect because 20 mg is too high for his renal function. Options B and D are incorrect because dabigatran is dosed twice daily, which conflicts with the patient's preference for a once-daily regimen, and the 110 mg dose is not FDA-approved for atrial fibrillation in the United States.
Question 7
A 79-year-old male on warfarin for atrial fibrillation presents for routine monitoring. He reports no bleeding or bruising. His current INR is 5.2. He recently completed a course of trimethoprim-sulfamethoxazole for a urinary tract infection. What is the most appropriate management plan?
- A) Administer oral vitamin K and recheck the INR.
- B) Omit one warfarin dose and reduce weekly dose.✓
- C) Stop warfarin entirely and start a novel agent.
- D) Send the patient to the emergency department now.
Show rationale
For a patient on warfarin with an INR between 4.5 and 10.0 and no evidence of bleeding, the standard of care is to omit one or two doses, monitor the INR, and adjust the maintenance dose downward. Trimethoprim-sulfamethoxazole is a known inhibitor of warfarin metabolism, causing this transient spike. Administering oral vitamin K is not recommended for an INR under 10.0 without bleeding, as it can cause prolonged warfarin resistance. Sending him to the emergency department is unnecessary without active hemorrhage. Switching agents abruptly while the INR is supratherapeutic increases bleeding risk.
Question 8
A 71-year-old female managed on warfarin reports a sudden increase in minor bruising over her arms and legs. She denies any recent falls or missed medication doses, but mentions she recently started drinking a new daily herbal tea blend for memory enhancement. Which action is the most appropriate initial step?
- A) Order an immediate prothrombin time and international normalized ratio.
- B) Inquire about the specific ingredients in the herbal tea.✓
- C) Advise the patient to stop drinking the herbal tea.
- D) Decrease her weekly warfarin dose to prevent severe bleeding.
Show rationale
A sudden increase in minor bruising in an older adult managed on warfarin who recently started a new daily herbal tea blend for memory enhancement strongly points to a drug-supplement interaction. The essential subjective assessment is to identify the specific ingredients in the tea, as many memory supplements like ginkgo biloba increase bleeding risks. Option A is an objective diagnostic test; while necessary, it does not fulfill the requirement to obtain subjective medication information first. Option C is a premature intervention before understanding exactly what the patient is consuming. Option D is an unsafe clinical adjustment without first confirming the INR and identifying the interacting substance. Thorough subjective inquiry prevents inappropriate dosing changes.
Question 9
A 71-year-old female presents with sudden, continuous vertigo, diplopia, and ataxia lasting 45 minutes. She has a history of atrial fibrillation off anticoagulation.
- A) Benign positional vertigo
- B) Acute vestibular neuritis
- C) Posterior circulation ischemia✓
- D) Meniere disease exacerbation
Show rationale
The combination of vertigo, diplopia, and ataxia strongly suggests posterior circulation ischemia, representing a vertebrobasilar TIA. The patient's unmanaged atrial fibrillation significantly increases her risk for an embolic event. While benign positional vertigo causes sudden dizziness, it is triggered by head movements, lasts only seconds, and lacks brainstem signs like diplopia. Acute vestibular neuritis causes continuous vertigo but is an isolated peripheral vestibular symptom without diplopia or profound ataxia. Meniere disease exacerbations present with vertigo, but they are classically accompanied by unilateral hearing loss, tinnitus, and aural fullness, rather than visual or cerebellar deficits.
Question 10
A 71-year-old male is transitioning from warfarin to apixaban for the management of his atrial fibrillation due to difficulty maintaining therapeutic levels. His current INR is 2.6 today in the clinic. What is the correct plan for initiating his new medication?
- A) Stop warfarin and initiate apixaban when INR is below 2.0.✓
- B) Stop warfarin and initiate apixaban when INR is below 3.0.
- C) Stop warfarin and initiate apixaban concurrently for the next week.
- D) Stop warfarin and initiate apixaban immediately during this current visit.
Show rationale
To safely transition a patient from warfarin to a direct oral anticoagulant, the provider must wait for the anticoagulant effect of warfarin to diminish to avoid compounding the bleeding risk. For apixaban and dabigatran, guidelines dictate that warfarin should be discontinued and the DOAC started when the INR falls below 2.0. Option B is incorrect because an INR threshold of less than 3.0 applies to transitioning to rivaroxaban, not apixaban. Options C and D are incorrect because overlapping the medications or starting apixaban while the INR is still therapeutic (2.6) would severely increase the patient's risk for a major hemorrhagic event.
Question 11
A patient with a mechanical mitral valve replacement presents with new-onset atrial fibrillation. The patient was recently discharged from an outside hospital with a prescription for dabigatran 150 mg twice daily. Which intervention is most appropriate for this patient?
- A) Continue the current dabigatran regimen without any changes.
- B) Switch to apixaban 5 mg twice daily instead.
- C) Transition the patient to an oral warfarin regimen.✓
- D) Reduce the dabigatran to 75 mg twice daily.
Show rationale
All direct oral anticoagulants, including dabigatran and apixaban, are strictly contraindicated in patients with mechanical heart valves due to a significantly increased risk of valve thrombosis, stroke, and major bleeding compared to traditional therapy. The only appropriate oral anticoagulant for this population is warfarin. Continuing dabigatran, switching to apixaban, or reducing the dabigatran dose all leave the patient at severe risk for catastrophic thromboembolic events and violate established cardiovascular guidelines.
Question 12
A patient taking rivaroxaban 20 mg daily for a pulmonary embolism is diagnosed with a severe respiratory infection. The covering provider prescribed clarithromycin, but the patient's chart flags an increased risk of bleeding. How should the advanced practice registered nurse manage this interaction?
- A) Discontinue the rivaroxaban during the oral antibiotic therapy.
- B) Change the antibiotic prescription to oral azithromycin therapy.✓
- C) Reduce the rivaroxaban prescription to 10 mg daily.
- D) Monitor the international normalized ratio during the therapy.
Show rationale
Clarithromycin is a strong dual inhibitor of both CYP3A4 and P-gp, which significantly decreases the clearance of rivaroxaban, leading to increased drug exposure and a high risk of major bleeding. Azithromycin does not share this strong inhibitory effect and is a safer macrolide alternative. Discontinuing the anticoagulant places the patient at high risk for recurrent pulmonary embolism. Reducing the rivaroxaban dose is not a standard evidence-based guideline for this specific short-term interaction. Monitoring the international normalized ratio is incorrect because it is not an accurate measure of direct oral anticoagulant activity.
Question 13
An 82-year-old female presents to the clinic to initiate anticoagulation for newly diagnosed non-valvular atrial fibrillation. Her current weight of 56 kg and her recent basic metabolic panel shows a serum creatinine 1.1 mg/dL. Which pharmacologic plan is most appropriate for this patient?
- A) Prescribe apixaban 2.5 mg by mouth twice daily.✓
- B) Prescribe apixaban 5.0 mg by mouth twice daily.
- C) Prescribe rivaroxaban 20 mg by mouth once daily.
- D) Prescribe rivaroxaban 15 mg by mouth once daily.
Show rationale
Standard dosing for apixaban in non-valvular atrial fibrillation is 5 mg twice daily. However, an apixaban dose reduction to 2.5 mg twice daily is required if the patient meets at least two of three criteria: age 80 years or older, body weight 60 kg or less, or serum creatinine 1.5 mg/dL or higher. This patient meets two criteria based on her age and weight, making option A the correct choice. Option B would overdose the patient and increase bleeding risk. Options C and D are incorrect because rivaroxaban dosing is based primarily on creatinine clearance, not this specific three-part criteria, and apixaban is generally preferred in frail older adults due to a more favorable safety profile.
Question 14
A 74-year-old male with atrial fibrillation reports new-onset fatigue, constipation, and muscle cramps over the past month. He takes apixaban, metoprolol, and amiodarone. His heart rate is 54 bpm.
- A) Decrease the metoprolol dose to improve bradycardia.
- B) Order a basic metabolic panel and electrocardiogram.
- C) Check a thyroid-stimulating hormone and free thyroxine.✓
- D) Recommend an over-the-counter daily osmotic bowel laxative.
Show rationale
Amiodarone contains a significantly high iodine load and is structurally similar to thyroid hormones, making it a common pharmacological cause of amiodarone-induced hypothyroidism, particularly in older adults. The patient's presentation of new-onset fatigue, constipation, and worsening bradycardia strongly suggests compromised thyroid function rather than simple beta-blocker toxicity or normal aging. You must check a thyroid-stimulating hormone and free thyroxine level to confirm the underlying endocrine diagnosis before making medication adjustments. Decreasing the metoprolol dose or recommending an over-the-counter daily osmotic bowel laxative only treats the superficial symptoms while ignoring the root medication-induced dysfunction. Ordering a basic metabolic panel and electrocardiogram is a reasonable step for general evaluation, but it completely misses the primary suspected etiology driving this specific cluster of new symptoms.
Question 15
A 71-year-old patient with severe osteoarthritis of the hip reports debilitating pain. Laboratory results reveal an eGFR of 28 mL/min/1.73 m2, and the patient has a history of gastrointestinal bleeding. Which pain management strategy is most appropriate?
- A) Order scheduled oral naproxen therapy
- B) Order scheduled oral celecoxib therapy
- C) Order scheduled oral duloxetine therapy
- D) Order intra-articular corticosteroid injection therapy✓
Show rationale
Patients with severe chronic kidney disease and a history of gastrointestinal bleeding have strict contraindications to systemic therapies. Intra-articular corticosteroids offer targeted relief without systemic toxicity. Both naproxen and celecoxib are NSAIDs that will worsen renal impairment and increase bleeding risk. Duloxetine is contraindicated in patients with an eGFR below 30 mL/min/1.73 m2 due to decreased clearance and increased toxicity.
